https://www.selleckchem.com/products/arry-382.html
BACKGROUND IRL752 is a novel small-molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex. OBJECTIVE The primary objective of the trial was to investigate the safety and tolerability of IRL752 in patients with Parkinson's disease and dementia. METHODS Patients with Parkinson's disease and dementia were randomized to IRL752 or placebo treatment (31 ratio) for 28 days. The study drug was given as an adjunct treatment to the patients' regular stable anti